Hepatocellular Carcinoma Treatment Study
This research study investigates the overall survival rate in patients diagnosed with unresectable hepatocellular carcinoma (HCC) using TheraSphere treatment with SOC sorafenib therapy vs SOC sorafenib alone. Overall, 600 patients will be recruited for this study. Rush University Medical Center expects to enroll 3 patients. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Have unresectable HCC.
- Be eligible to receive standard-of-care sorafenib.
You will be excluded from the study if any of the following criteria apply to you:
- Have main portal vein thrombosis (PVT).
- Have had a liver transplant.
- Have already been treated with TACE, yttrium-90 or sorafenib within 2 months of randomization).
This is a partial list of inclusion and exclusion criteria.